Moderna said it is looking for growth overseas after the U.S. FDA refused to review its experimental flu shot and the country’s top health officials have deprioritized vaccination.

Analysis - We are now approaching six years since COVID-19 was declared a pandemic by the World Health Organization, yet talk of vaccines and our immune systems persists in our cultural conversations ...

After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out on as other nations embrace the technology.

In fact, in 2022, the Liberal government needlessly enacted Canada’s Emergencies Act and violated the Canadian Charter of Rights and Freedoms itself, in a shameful effort to oppress the Freedom Convoy ...

A rare but serious clotting disorder linked to certain COVID-19 vaccines and natural adenovirus infections has puzzled scientists for years.

Moderna is shifting its focus internationally following the U.S. FDA's refusal to review its flu shot. The company plans to ...

Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.

The FDA’s refuse-to-file letter cited no safety or efficacy concerns for Moderna’s influenza vaccine, mRNA-1010. The company said the agency’s justification for refusing a review is inconsistent with ...

Moderna's shares drop over 10% following the FDA's decision to decline reviewing its experimental flu vaccine. Changes in U.S. vaccine policy have impacted public health and stalled Moderna's mRNA ...

FDA refuses Moderna's mRNA flu vaccine application, citing inadequate study design, as the company disputes decision, saying it contradicts prior FDA guidance.

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.